MedTrace Logo

Vit D3 for Early Symptoms of COVID-19

NCT05008003 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-04-04

No results posted yet for this study

Summary

This study is aimed to investigate the treatment vitamin D3 as complementary therapy with routine care for early mild symptoms of COVID-19 in outpatients setting.

Conditions

  • Covid19

Interventions

DRUG

Standard of care

Standard of care treatment as per the hospital guidelines

DIETARY_SUPPLEMENT

Vitamin D3

A daily dose of 5000 IU vitamin D3 for 7 days.

Sponsors & Collaborators

  • Liaquat University of Medical & Health Sciences

    collaborator OTHER

  • Ayub Teaching Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-02
Primary Completion
2023-03-01
Completion
2023-04-30

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05008003 on ClinicalTrials.gov